National Haemoglobinopathy Panel

A core function of the NHP is to provide a monthly MDT meeting where complex cases from across the country can get evidence-based guidance on individual patient care and sound clinical and professional learning.

The MDT is also a forum for authorising specialist, new and novel use of therapies, such as Stem Cell Transplantation, Gene Therapy and monoclonal antibodies. The NHP welcomes referrals from physicians caring for Sickle Cell, Thalassaemia and Rare Inherited Anaemia patients, though advises the preference for cases to be discussed first in the HCC MDT where possible.